TransCode Therapeutics Inc

NASDAQ:RNAZ  
2.05
-0.04 (-1.91%)
Other Pre-Announcement

TransCode Therapeutics Reports Business Progress And Second Quarter 2021 Financial Results

Published: 08/23/2021 20:10 GMT
TransCode Therapeutics Inc (RNAZ) - Transcode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results.
Q2 Earnings per Share $0.51.
On Track to Submit Eind Application for Ttx-mc138 in Q1 2022.
Transcode - Expects Cash,cash Equivalents As of June 30, With Net Proceeds From Ipo, Sbir Award, Enough to Fund Planned Operations Through Year-end 2022.